(NASDAQ: EQ) Equillium's forecast annual revenue growth rate of -43.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Equillium's revenue in 2025 is $41,095,000.On average, 1 Wall Street analysts forecast EQ's revenue for 2026 to be $554,802,351, with the lowest EQ revenue forecast at $554,802,351, and the highest EQ revenue forecast at $554,802,351. On average, 1 Wall Street analysts forecast EQ's revenue for 2027 to be $588,275,664, with the lowest EQ revenue forecast at $588,275,664, and the highest EQ revenue forecast at $588,275,664.
In 2028, EQ is forecast to generate $1,840,676,093 in revenue, with the lowest revenue forecast at $1,840,676,093 and the highest revenue forecast at $1,840,676,093.